Ortho Regenerative Technologies was issued U.S. Patent No. 11,285,100 B2, Freeze-Dried Polymer Compositions for mixing with platelet-rich plasma to form implants for tissue repair and/or composition for therapeutic intra-articular injection. The patent provides protection for both the composition and the method of use of Ortho R Technology.
ORTHO-R, a Chitosan/PRP hybrid drug/biologic implant combination product, is formulated and designed to increase the healing rates of occupational and sports related injuries to tendons, meniscus and ligaments. Other formulations are being developed for cartilage repair, bone void filling and osteoarthritis treatment.
“This U.S. patent is a critical step in protecting our technology platform in the world’s largest orthopedic soft tissue repair market and provides further validation of our novel and unique approach to soft tissue repair regenerative technologies. Receiving this patent from the USPTO is a key, hard fought, value creation milestone for the company,” said CEO Philippe Deschamps.
Ortho Regenerative Technologies was issued U.S. Patent No. 11,285,100 B2, Freeze-Dried Polymer Compositions for mixing with platelet-rich plasma to form implants for tissue repair and/or composition for therapeutic intra-articular injection. The patent provides protection for both the composition and the method of use of Ortho R Technology. ...
Ortho Regenerative Technologies was issued U.S. Patent No. 11,285,100 B2, Freeze-Dried Polymer Compositions for mixing with platelet-rich plasma to form implants for tissue repair and/or composition for therapeutic intra-articular injection. The patent provides protection for both the composition and the method of use of Ortho R Technology.
ORTHO-R, a Chitosan/PRP hybrid drug/biologic implant combination product, is formulated and designed to increase the healing rates of occupational and sports related injuries to tendons, meniscus and ligaments. Other formulations are being developed for cartilage repair, bone void filling and osteoarthritis treatment.
“This U.S. patent is a critical step in protecting our technology platform in the world’s largest orthopedic soft tissue repair market and provides further validation of our novel and unique approach to soft tissue repair regenerative technologies. Receiving this patent from the USPTO is a key, hard fought, value creation milestone for the company,” said CEO Philippe Deschamps.
Copy to clipboard 
